

PART OF THE FLORETINA CONGRESS

FLORENCE, ITALY  
DECEMBER 4-6, 2025



Retinal disease research,  
innovation, prevention and care



## PROGRAM

### THURSDAY 4 DECEMBER

#### SAN GIOVANNI ROOM

#### 16.45-18.00 RETINA FUTURA - NEOVASCULAR AMD

*Moderators:*

VAJZOVIC	LEJLA
RACHITSKAYA	ALEKSANDRA
REGILLO	CARL D.
BANDELLO	FRANCESCO

16:45	0:03	<b>RIZZO</b>	STANISLAO	Introduction
16:48	0:03	<b>FARALDI</b>	FRANCESCO	Upcoming solutions for unmet needs: new drugs for retinal treatments. Program overview
16:51	0:04	<b>PAULEIKHOFF</b>	DANIEL	Macular Atrophy under long term Anti-VEGF therapy – a challenge for visual prognosis?
16:55	0:04	<b>LOEWENSTEIN</b>	ANAT	Fibrosis as a limiting factor in visual acuity outcome in neovascular macular degeneration
16:59	0:04	<b>KAISER</b>	PETER	Gene therapy for wet AMD
17:03	0:04	<b>LENG</b>	THEODORE	The science behind next-generation long-acting ocular biologics: harnessing antibody biopolymer conjugates to optimize immediacy and durability
17:07	0:04	<b>AVERY</b>	BOB	Subretinal Delivery of Gene Therapy ABBV-RGX-314: Status of the Largest Investigational Gene Therapy Program in Chronic Retinal Disease
17:11	0:04	<b>CHAKRAVARTHY</b>	USHA	EYP 1901 in nAMD: Updated Davio 2 Results
17:15	0:04	<b>AWH</b>	CARL	PRISM Phase 1/2 Study of 4D-150 in Wet AMD: 18-24 Months Extended Follow-Up, First Time Results
17:19	0:04	<b>REGILLO</b>	CARL D.	PDS longterm vision outcomes over 5-7 years
17:23	0:04	<b>WYKOFF</b>	CHARLES C.	Ixo—vec Gene Therapy for nAMD: Clinical Progress from the LUNA Phase 2 Trials / Introduction to the ARTEMIS Phase 3 Study
17:27	0:04	<b>ROMANO</b>	MARIO	Aligning policies with real-world medical needs. The bridging role of HCP organisations in the EMA-ECHA regulatory overlap. Case study: The Universal PFAS Ban
17:27	0:33			<b>Panel discussion: Durability for efficacy bridging science and policy</b>
		<b>BANDELLO</b>	FRANCESCO	<i>Moderator</i>
		<b>VAJZOVIC</b>	LEJLA	<i>Moderator</i>
		<b>ALLAMPRESE</b>	MICHELE	<i>Panelist</i>
		<b>BERNARDINI</b>	RENATO	<i>Panelist</i>
		<b>DESAI</b>	DHAVAL	<i>Panelist</i>
		<b>DUKER</b>	JAY	<i>Panelist</i>
		<b>HOLZ</b>	FRANK	<i>Panelist</i>
		<b>PALANKI</b>	RAM	<i>Panelist</i>
		<b>REGILLO</b>	CARL D.	<i>Panelist</i>
		<b>RACHITSKAYA</b>	ALEKSANDRA	<i>Panelist</i>
		<b>ROMANO</b>	MARIO	<i>Panelist</i>

### FRIDAY 5 DECEMBER

**FLORetina-ICOOR Meeting 2025 jointly organized with World ROP Congress  
RETINA FUTURA PROGRAM**

**SAN GIOVANNI ROOM**

**11.30-12.45 RETINA FUTURA - TRENDS IN DIABETIC RETINOPATHY, DME AND OTHER MACULAR EDEMAS**

*Moderators:*

LOEWENSTEIN	ANAT
KUPPERMANN	BARUCH
NGUYEN	QUAN DONG
STANGA	PAULO EDUARDO

11:30	0:02		Introduction by the moderators
11:32	0:04	<b>BANDELLO</b>	FRANCESCO The neurovascular impairment in diabetic retinopathy and its influence on the course of the disease
11:36	0:04	<b>KUPPERMANN</b>	BARUCH New Advances in Drug Delivery for the Treatment of Posterior Segment Diseases
11:40	0:04	<b>NGUYEN</b>	QUAN DONG Inhibiting Interleukin-6 in Diabetic Macular Edema and Inflammatory Macular Edema
11:44	0:04	<b>FERRONE</b>	PHILIP 60-week results from the Phase 2 SPECTRA Clinical Trial Evaluating the Intravitreal Genetic Medicine 4D-150 in Adults with Diabetic Macular Edema
11:48	0:04	<b>DHOOT</b>	DILSHER Suprachoroidal gene therapy for diabetic retinopathy, Update on the ABBV-RGX-14 Program
11:52	0:04	<b>VAJZOVIC</b>	LEJLA Suprachoroidal Gene Therapy Surabgene Lomparovec (Sura-vec, ABBV-RGX-314): 2-Year Results in Non-Proliferative Diabetic Retinopathy
11:56	0:04	<b>NGUYEN</b>	QUAN DONG Targeting Retinal Non-Perfusion in Diabetic Retinopathy with BI 764524
12:00	0:04	<b>STANGA</b>	PAULO EDUARDO Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with either non-proliferative Diabetic Retinopathy or recent onset Retinal Vein Occlusion
12:04	0:04	<b>REGILLO</b>	CARL D. EYP1901 VERONA Phase 2 trial results for the treatment of diabetic macular edema
12:08	0:04	<b>WYKOFF</b>	CHARLES C. Encapsulated Cell Therapy Revakinagene Taroretcel (NT-501) for the Management of MacTel Type 2
12:12	0:04	<b>BAKRI</b>	SOPHIE J. Update on anti-IL-6 Vamikibart for Uveitis Macular Edema
12:16	0:04	<b>KUPPERMANN</b>	BARUCH Restoret (MK-3000) for the Treatment of Diabetic Macular Edema: Results from the AMARONE Phase 1b/2a Clinical Trial
12:20	0:25		<b>Panel discussion: Long-Lasting Therapies in DR, DME and macular edemas</b>
		<b>LOEWENSTEIN</b>	ANAT <i>Moderator</i>
		<b>STANGA</b>	PAULO EDUARDO <i>Moderator</i>
		<b>AWH</b>	CARL <i>Panelist</i>
		<b>KUPPERMANN</b>	BARUCH <i>Panelist</i>
		<b>STANGA</b>	PAULO EDUARDO <i>Panelist</i>
		<b>RIBEIRO</b>	RAMIRO <i>Panelist</i>
		<b>PAKOLA</b>	STEVE <i>Panelist</i>

**SATURDAY 6 DECEMBER**

**SANTA CROCE ROOM**

**11.00-12.30 RETINA FUTURA - SPOTLIGHT ON EMERGING THERAPIES FOR INHERITED RETINAL DISEASES (IRDs)**

*Moderators:*

HO	ALLEN
LEROY	BART
MACLAREN	ROBERT
SIMONELLI	FRANCESCA
FERRONE	PHILIP

11:00	0:02		Introduction by the moderators
11:02	0:04	<b>FERRONE</b>	PHILIP Gildeuretinol in Stargardt Disease: Results from the TEASE-2 Program
11:06	0:04	<b>RACHITSKAYA</b>	ALEKSANDRA Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN Trial, preliminary month 9+ results
11:10	0:04	<b>HENDERSON</b>	ROBERT Battens disease therapies - enzyme replacement and gene therapy
11:14	0:04	<b>LEROY</b>	BART AAVB-039 program - a dual AAV8.ABCA4 gene therapy for patients with Stargardt's disease
11:18	0:04	<b>HO</b>	ALLEN Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa
11:22	0:04	<b>SIMONELLI</b>	FRANCESCA Preliminary results of AAVB-081 - First-in-Human Phase I/II Trial of Gene Therapy of Retinitis Pigmentosa in Subjects with Usher syndrome Type 1B

**FLORetina-ICOOR Meeting 2025 jointly organized with World ROP Congress  
RETINA FUTURA PROGRAM**

11:26	0:04	<b>VAJZOVIC</b>	LEJLA	Novel Modifier Gene Therapy for Stargardt Disease (OCU410ST): Phase 1/2 Clinical Trial Update
11:30	0:04	<b>NIESEN</b>	TOBIAS	CLARICO: A Phase 1/2a Study of OpCT-001 Cell Therapy for Primary Photoreceptor Diseases
11:34	0:04	<b>NGUYEN</b>	QUAN DONG	Tinlarebant for Adolescent Stargardt's Disease: Interim Results of Phase 3 DRAGON Study
11:38	0:04	<b>LEROY</b>	BART	Antisense Oligonucleotides for IRDs
11:42	0:04	<b>TESTA</b>	FRANCESCO	A natural history study for CRX-related retinal dystrophies in preparation of a phase I clinical trial
11:46	0:44	<b>Panel discussion: Biomarkers</b>		
		<b>HO</b>	ALLEN	<i>Moderator</i>
		<b>LEROY</b>	BART	<i>Moderator</i>
		<b>LEROY</b>	BART	<i>Panelist</i>
		<b>MACLAREN</b>	ROBERT	<i>Panelist</i>
		<b>SIMONELLI</b>	FRANCESCA	<i>Panelist</i>
		<b>FERRONE</b>	PHILIP	<i>Panelist</i>
		<b>BERNARDINI</b>	RENATO	<i>Panelist</i>
		<b>CHUNG</b>	DAN	<i>Panelist</i>
		<b>SCHOLL</b>	HENDRIK	<i>Panelist</i>

## SATURDAY 6 DECEMBER

### SAN GIOVANNI ROOM

**16.15-17.45 RETINA FUTURA - HIGHLIGHTS IN GEOGRAPHIC ATROPHY (GA): CURRENT CLINICAL UPDATES AND EMERGING THERAPIES**

*Moderators:*

HOLZ	FRANK
MONES	JORDI

16:15	0:02	Introduction by the moderators		
16:17	0:04	<b>HOLZ</b>	FRANK	AI-Powered Assessment of Retinal Function: From OCT to High-Definition Sensitivity Maps
16:21	0:04	<b>WYKOFF</b>	CHARLES C.	GA Treatment by C3 Inhibition: Phase 1 Outcomes and Ongoing Phase 2 Trial (VERDANT) Design for the Novel Biologic BI-771716
16:25	0:04	<b>DHOOT</b>	DILSHER	Safety and Efficacy of Oral Gildeuretinol in Geographic Atrophy: Results of SAGA, a Phase 2/3 Clinical Study
16:29	0:04	<b>KUPPERMANN</b>	BARUCH	Advancing Geographic Atrophy Treatment with ONL1204: Insights from the Phase 1b Study and Phase 2 Launch
16:33	0:04	<b>CHIDAMBARAM</b>	JAYA	Preliminary Safety and Efficacy Results from a Phase 1b Allogenic RPE Cell Therapy Trial in Patients with GA Secondary to AMD
16:37	0:04	<b>LUPIDI</b>	MARCO	A Novel Systemic Approach to Geographic Atrophy With Pozelimab Plus Cemdisiran or Cemdisiran Alone: The Phase 3 SIENNA Study Design
16:41	0:04	<b>HADZIAHMETOVIC</b>	MAJDA	Novel Modifier Gene Therapy for Geographic Atrophy (OCU410): Phase 1/2 Clinical Trial Update
16:45	0:04	<b>KAISER</b>	PETER	Updates from the ReNEW Phase 3 Trial
16:49	0:04	<b>BACHERINI</b>	DANIELA	Intravitreal mAb for the Treatment of GA: Updates from the ARCHER II Clinical Study
16:53	0:04	<b>SCHMIDT-ERFURTH</b>	URSULA	Targeted Microperimetry: Understanding functional loss in AMD
16:57	0:48	<b>Panel discussion: Future therapies for dry AMD: biomarkers and regulatory processes</b>		
		<b>MONES</b>	JORDI	<i>Moderator</i>
		<b>HOLZ</b>	FRANK	<i>Panelist</i>
		<b>TAYLOR</b>	LORI	<i>Panelist</i>
		<b>HASSAN</b>	TAREK	<i>Panelist</i>
		<b>WANT</b>	ANDREW	<i>Panelist</i>